1-19 of 19 Results

Title Investigator Disease(s)

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

[Protocol 17-1026]
Margaret von Mehren
  • Colon
  • A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

    [Protocol 19-1007]
    David Weinberg
  • Colon
  • AMG510 in Subjects w/Advanced Solid Tumors with Specific KRAS Mutation

    [Protocol 18-1061]
    Crystal Denlinger
  • Colon
  • Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer

    [Protocol 18-2004]
    Juhi Mittal
  • Colon
  • Anti-TIM-3 mAB BGB-A425 w/Anti-PD-1 mAB Tislelizumab in Pts w/Solid Tumors

    [Protocol 18-1045]
    Crystal Denlinger
  • Colon
  • Assessing M3541 in Combination with Palliative Radiotherapy in Solid Tumors

    [Protocol 17-1042]
    Anthony Olszanski
  • Colon
  • Cabozantinib With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

    [Protocol 19-1004]
    Crystal Denlinger
  • Colon
  • Crenolanib in Pts w/Metastatic Gastrointestinal Stromal Tumors w/a D842V Mutation in the PDGFRA Gene

    [Protocol 16-1063]
    Margaret von Mehren
  • Colon
  • Evaluation of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors

    [Protocol 17-1051]
    Anthony Olszanski
  • Colon
  • Evaluation of BMS-986226 Alone or in Combination w/Opdivo or Yervoy in Pts w/Advanced Solid Tumors

    [Protocol 17-1046]
    Jessica Bauman
  • Colon
  • FIH all-comers of DSP-0509 TLR-7 agonist.

    [Protocol 18-1030]
    Anthony Olszanski
  • Colon
  • GSK3359609 Alone and in Combination w/Anticancer Agents in Subjects w/Selected Advanced Solid Tumors

    [Protocol 16-1071]
    Anthony Olszanski
  • Colon
  • Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

    [Protocol 17-1022]
    Anthony Olszanski
  • Colon
  • KO-947 in Advanced Unresectable Metastatic Relapsed and/or Refractory Non-Hematological Malignancies

    [Protocol 16-1101]
    Anthony Olszanski
  • Colon
  • Molecular Analysis for Therapy Choice (MATCH)

    [Protocol 15-7002]
    Lori Goldstein
  • Colon
  • ONC201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

    [Protocol 15-1009]
    Anthony Olszanski
  • Colon
  • Perioperative Risk study in Patients Undergoing Elective Major Cancer Surgery

    [Protocol 14-036]
    Marc Smaldone
  • Colon
  • TAK-981 Sumoylation FIH study

    [Protocol 18-1038]
    Anthony Olszanski
  • Colon
  • Tecentriq with Taxol, Herceptin, and Perjeta in treating Metastatic HER-2 Positive Breast Cancer

    [Protocol 17-1010]
    Lori Goldstein
  • Colon